Examining the Use of Tramadol Hydrochloride as an Antidepressant

Experimental and Clinical Psychopharmacology

Volumn 19, Issue 2, 2011, Pages 123-130

  Barber, Justin ^a  

^a UNIVERSITY OF SOUTH CAROLINA BEAUFORT   (United States)

Author keywords

Depression; Monoamine; Next generation antidepressants; Opiate; Opioid; Serotonin; SNRI; SSRI; Tramadol

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; DULOXETINE; MIRTAZAPINE; MU OPIATE RECEPTOR; NORADRENALIN; PARACETAMOL PLUS TRAMADOL; SEROTONIN; TRAMADOL; VENLAFAXINE;

ARTICLE; DEPRESSION; DRUG MECHANISM; HUMAN; NONHUMAN; RESPIRATION DEPRESSION; RISK FACTOR; SEIZURE; SLEEP; SUBSTANCE ABUSE;

ANALGESICS, OPIOID; ANIMALS; ANTIDEPRESSIVE AGENTS; DRUG TOLERANCE; HUMANS; MICE; RATS; RESPIRATION; SEIZURES; SLEEP; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TRAMADOL;

EID: 79954493674     PISSN: 10641297     EISSN: 19362293     Source Type: Journal    
DOI: 10.1037/a0022721     Document Type: Article

References (89)

1. Adams E.H., Breiner S., Cicero T.J., Geller A., Inciardi J.A., Schnoll S.H., Woody G.E. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. Journal of Pain and Symptom Management 2006, 31:465-476.
2. Adell A., Castro E., Celada P., Bortolozzi A., Pazos A., Artigas F. Strategies for producing faster acting antidepressants. Drug Discovery Today 2005, 10:578-585.
3. Allen K. Interference by venlafaxine ingestion in the detection of tramadol by liquid chromatography linked to tandem mass spectrometry for the screening of illicit drugs in human urine. Clinical Toxicology (Philadelphia) 2006, 44:147-153.
4. The diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, American Psychiatric Association, Washington, DC. 4th ed., text revision.
5. Bamigbade T.A., Davidson C., Langford R.M., Stamford J.A. Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. British Journal of Anesthesia 1997, 79:352-356.
6. Baraldi M., Poggioli R., Santi M., Vergoni A.V., Bertolini A. Antidepressants and opiates interactions: Pharmacological and biochemical evidences. Pharmacological Research Communications 1983, 15:843-857.
7. Berrocoso E., Sanchez-Blazquez P., Garzon J., Mico J.A. Opiates as antidepressants. Current Pharmaceutical Design 2009, 15:1612-1622.
8. Blazer D.G. The evolution of depression as a diagnosis. The age of melancholy: " Major depression" and its social origins 2005, 41-55. Taylor & Francis Group, New York.
9. 3 receptor agonist, in olfactory bulbectomized rats. European Journal of Pharmacology 2009, 6:134-140.
10. Budd K. The role of tramadol in acute pain management. Acute Pain 1999, 2:189-196.
11. Burnett F., Scott L., Weaver M., Medbak S., Dinan T. The effect of naloxone on adrenocorticotropin and cortisol release: Evidence for a reduced response in depression. Journal of Affective Disorders 1999, 53:263-268.
12. Clarot F., Goullé J.P., Vaz E., Proust B. Fatal overdoses of tramadol, is benzodiazepine a risk factor of lethality?. Forensic Science International 2003, 134:57-61.
13. Corbett A.D., Henderson G., McKnight A.T., Paterson S.J. 75 years of opioid research: The exciting but vain quest for the Holy Grail. British Journal of Pharmacology 2006, 147:153-162.
14. Davis W., Johnson B. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug and Alcohol Dependence 2008, 92:267-276.
15. DiMatteo V., DeBlasi A., DiGiulio C., Esposito E. Role of 5-HT2C receptors in the control of central dopamine function. TRENDS in Pharmacological Sciences 2001, 22:229-232.
16. Dimsdale J., Norman D., DeJardin D., Wallace M. The effect of opioids on sleep architecture. Journal of Clinical Sleep Medicine: Official Publication of the American Academy of Sleep Medicine 2007, 3:33-36.
17. Doggett N., Reno H., Spencer P. Narcotic agonists and antagonists as models for potential antidepressant drugs. Neuropharmacology 1975, 14:507-515.
18. Drug topics. (2008). Top 200 brand and generic drugs of 2007. Drug topics, February 18, 2008. Retrieved from http://drugtopics.modernmedicine.com/.
19. Elhwuegi A. Central monoamines and their role in major depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004, 28:435-451.
20. Escriba P.V., Ozaita A., Garcia-Sevilla J.A. Increased mRNA expression of receptors in the brains of suicide victims. Neuropsychopharmacology 2004, 29:1512-1521.
21. Extein I., Pottash A., Gold M. A possible opioid receptor dysfunction in some depressive disorders. Annals of the New York Academy of Sciences 1982, 398:113-119.
22. 2-adrenergic receptors in the rat brain. Brain Research 2004, 1016:263-267.
23. Fine P., Portenoy R.K. The endogenous opioid systems (chapter 2). Opioid analgesia book 2004, McGraw-Hill, New York.
24. Flick K., Frankus E. U.S. Patent No. 3,652,589 1972, U.S. Patent and Trademark Office, Washington, DC.
25. Gervasoni D., Panconi E., Henninot V., Boissard R., Barbagli B., Fort P., Luppi P.H. Effect of chronic treatment with milnacipran on sleep architecture in rats compared with paroxetine and imipramine. Pharmacology, Biochemistry, and Behavior 2002, 73:557-563.
26. Gold M., Pottash A., Sweeney D., Martin D., Extein I. Antimanic, antidepressant, and antipanic effects of opiates: Clinical, neuroanatomical, and biochemical evidence 1982.
27. Goldsmith T.B., Shapira N.A., Keck P.E. Rapid remission of OCD with tramadol hydrochloride. American Journal of Psychiatry 1999, 156:660-661.
28. Hopwood S., Owesson C., Callado L., McLaughlin D., Stamford J. Effects of chronic tramadol on pre- and post-synaptic measures of monoamine function. [Abstract]. Journal of Psychopharmacology 2001, 15:147-153.
29. Hosobuchi Y., Lamb S., Bascom D. Tryptophan loading may reverse tolerance to opiate analgesics in humans: A preliminary report. Pain 1980, 9:161-169.
30. Hummel T., Kraetsch H., Lötsch J., Hepper M. Analgesic effects of dihydrocodeine and tramadol when administered either in the morning or evening. [Abstract]. Chronobiology International 1995, 12:62-72.
31. Ide S., Minami M., Ishihara K., Uhl G.R., Sora I., Ikeda K. Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology 2006, 51:651-658.
32. Inciardi J.A., Cicero T.J., Muñoz A., Adams E.H., Gellar A., Senay E.C., Woody G.E. The diversion of Ultram, Ultracet, and generic tramadol HCl. Journal of Addictive Diseases 2006, 25:53-58.
33. Jesse C.R., Wilhelm E.A., Bortolatto C.F., Nogueira C.W. Evidence for the involvement of the noradrenergic system, dopaminergic and imidazoline receptors in the antidepressant-like effect of tramadol in mice. Pharmacology, Biochemistry and Behavior 2010, 95:344-350.
34. Jovanović-Cupić V., Martinović Z., Nesić N. Seizures associated with intoxication and abuse of tramadol. Clinical Toxicology 2006, 44:143-146.
35. Julien R.M., Advokat C.D., Comaty J.E. A primer of drug action 2008, Worth Publishers, New York.
36. Jutkiewicz E. The antidepressant-like effects of delta-opioid receptor agonists. Molecular Interventions 2006, 6:162-169.
37. Kalra B., Tayal V., Chawla S. Antidepressant-like activity of tramadol in mice. Indian Journal of Psychiatry 2008, 50:51-53.
38. Katona C., Peveler R., Dowrick C., Wessely S., Feinmann C., Gask L., Wager E. Pain symptoms in depression: Definition and clinical significance. Clinical Medicine 2005, 5:390-395.
39. Kellstein D., Malseed R., Ossipov M., Goldstein F. Effect of chronic treatment with tricyclic antidepressants upon antinociception induced by intrathecal injection of morphine and monoamines. Neuropharmacology 1988, 27:1-14.
40. Klauenberg S., Maier C., Assion H.J., Hoffman A., Krumova E.K., Magerl W., Juckel G. Depression and changed pain perception: Hints for a central disinhibition mechanism. Pain 2008, 140:332-343.
41. Kline N. Beta-endorphin-induced changes in schizophrenic and depressed patients. [Abstract]. Archives of General Psychiatry 1977, 34:1111-1113.
42. Knisely J.S., Campbell E.D., Dawson K.S., Schnoll S.H. Tramadol post-marketing surveillance in health care professionals. Drug and Alcohol Dependence 2002, 68:15-22.
43. Kuo S., Lin Y., Kao S., Kao Yang Y. Probably codeine phosphate-induced seizures. The Annals of Pharmacotherapy 2004, 36:1848-1851.
44. Lee C.R., McTavish D., Sorkin E.M. Tramadol: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993, 46:313-340.
45. Markowitz J.S., Patrick K.S. Venlafaxine-tramadol similarities. Medical Hypotheses 1998, 51:167-168.
46. Masand P., Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Annals of Clinical Psychiatry 2002, 14:175-182.
47. Matthiesen T., Wöhrmann T., Coogan T.P., Uragg H. The experimental toxicology of tramadol: An overview. Toxicology Letters 1998, 95:63-71.
48. McCabe S., Cranford J., Boyd C., Teter C. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addictive Behaviors 2007, 32:562-575.
49. McQuay H.J., Tramèr M., Nye B.A., Carroll D., Wiffen P.J., Moore R.A. A systematic review of antidepressants in neuropathic pain. Pain 1996, 68:217-227.
50. Micó J.A., Rojas-Corrales M.O., Moreno-Brea M.R., Ortego-Alvara A., Roca-Vicardell A., Gibert-Rahola J. Effectiveness of tramadol as antidepressant in the learned-helplessness model of depression. European Neuropsychopharmacology 2003, 10:251-252.
51. 2C receptors as a target for the treatment of depressive and anxious states: Focus on novel therapeutic strategies. [Abstract] Therapie 2005, 60:441-460.
52. Miranda H., Pinardi G. Antinociception, tolerance, and physical dependence comparison between morphine and tramadol. Pharmacology, Biochemistry, and Behavior 1998, 61:357-360.
53. 2C receptor: Alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology 2001, 24:478-491.
54. Ogata J., Minami K., Uezono Y., Okamoto T., Shiraishi M., Shigematsu A., Ueta Y. Inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in xenopus oocytes. Anesthesia & Analgesia 2004, 98:1401-1406.
55. Onali P., Dedoni S., Olianas M. Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. The Journal of Pharmacology and Experimental Therapeutics 2010, 332:255-265.
56. Potschka H., Friderichs E., Löscher W. Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. British Journal of Pharmacology 2000, 131:203-212.
57. Pundiak T., Case B., Peselow E., Mulcare L. Discontinuation of maintenance selective serotonin reuptake inhibitor monotherapy after 5 years of stable response: A naturalistic study. Journal of Clinical Psychiatry 2008, 69:1811-1817.
58. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd R.P., Vaught J.L. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. The Journal of Pharmacology and Experimental Therapeutics 1992, 260:275-285.
59. Raffa R.B., Stone D.J. Unexceptional seizure potential of tramadol or its enantiomers or metabolites in mice. The Journal of Pharmacology and Experimental Therapeutics 2008, 325:500-506.
60. Ressler K., Nemeroff C. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biological Psychiatry 1999, 46:1219-1233.
61. Ritvo J.I., Koonce R., Thurstone C.C., Causey H.L. Tramadol dependence: Treatment with buprenorphine/naloxone. The American Journal of Addictions 2007, 16:67-68.
62. 1B receptors in the antinociceptive effect of tramadol. European Journal of Pharmacology 2005, 511:21-26.
63. Salín-Pascual R., Galicia-Polo L., Drucker-Colín R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. Journal of Clinical Psychiatry 1997, 58:348-350.
64. Schechter L., Ring R., Beyer C., Hughes Z., Khawaja X., Malberg J., Rosenzweig-Lipson S. Innovative approaches for the development of antidepressant drugs: Current and future strategies. NeuroRx: The Journal of the American Society for Experimental Neurotherapeutics 2005, 2:590-611.
65. Schreiber S., Backer M., Kaufman J., Pick C. Interaction between the tetracyclic antidepressant mianserin HCl and opioid receptors. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 1998, 8:297-302.
66. Schreiber S., Backer M.M., Pick C.G. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neuroscience Letters 1999, 273:85-88.
67. Senay E.C., Adams E.H., Geller A., Inciardi J.A., Muñoz A., Schnoll S.H., Cicero T.J. Physical dependence on ultram (tramadol hydrochloride): Both opioid-like and atypical symptoms occur. Drug and Alcohol Dependence 2003, 69:233-241.
68. Shapira N.A., Keck P.E., Goldsmith T.D., McConville B.J., Eis M., McElroy S.L. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depression and Anxiety 1997, 6:170-173.
69. Shapira N.A., Verduin M.L., DeGraw J.D. Treatment of refractory major depression with tramadol monotherapy. Journal of Clinical Psychiatry 2001, 62:205-206.
70. Sher L. Role of endogenous opioids in the effects of light on mood and behavior. Medical Hypotheses 2001, 57:609-611.
71. Shiga Y., Minami K., Shiraishi M., Uezono Y., Murasaki O., Kaibara M., Shigematsu A. The inhibitory effects of tramadol on muscarinic receptor-induced responses in Xenopus oocytes expressing cloned M(3) receptors. Anesthesia and Analgesia 2002, 95:1269.
72. Shiraishi M., Minami K., Uezono Y., Yanagihara N., Shigematsu A., Shibuya I. Inhibitory effects of tramadol on nicotinic acetylcholine receptors in adrenal chromaffin cells and in xenopus oocytes expressing alpha 7 receptors. British Journal of Pharmacology 2002, 136:207-216.
73. Sinclair L., Christmas D., Hood S., Potokar J., Robertson A., Isaac A., Davies S.J.C. Antidepressant-induced jitteriness/anxiety syndrome: Systematic review. British Journal of Psychiatry 2009, 194:483-490.
74. Singh V., Jain N., Kulkarni S. On the antinociceptive effect of fluoxetine, a selective serotonin reuptake inhibitor. Brain Research 2001, 915:218-226.
75. Skipper G.E., Fletcher C., Rocha-Judd R. Tramadol abuse and dependence among physicians. Journal of American Medical Association 2004, 292:1818-1819.
76. Spencer C. The efficacy of intramuscular tramadol as a rapid-onset antidepressant. The Australian and New Zealand Journal of Psychiatry 2000, 34:1032-1033.
77. Stoehr J., Essary A., Ou C., Ashby R., Sucher M. The risk of tramadol abuse and dependence: Findings in two patients. JAAPA: Official Journal of the American Academy of Physician Assistants 2009, 22:31.
78. Stoll A., Rueter S. Treatment augmentation with opiates in severe and refractory major depression. The American Journal of Psychiatry 1999, 156:2017.
79. The NSDUH Report: Nonmedical use of prescription pain relievers 2005, Substance Abuse and Mental Health Services Administration, Retrieved from http://oas.samhsa.gov/2k4/pain/pain.pdf.
80. Tarikka P., Tuominen M., Lindgren L. Comparison of respiratory effects of tramadol and oxycodone. Journal of Clinical Anesthesia 1997, 9:582-585.
81. Tejedor-Real P., Mico J., Maldonado R., Roques B. Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacology, Biochemistry and Behavior 1995, 52:145-152.
82. Ultram ER. Physicians' Desk Reference 2009, 64:2693-2697. PDR Network, LLC, Montvale, NJ.
83. Vickers M.D., O'Flaherty D., Szekely S.M., Read N., Yoshizumi J. Tramadol: Pain relief by an opioid without depression of respiration. [Abstract] Anaesthesia 1992, 47:291-296.
84. Walder B., Tramer M.R., Blois R. The effects of single doses of tramadol on sleep: A randomized cross-trial in healthy volunteers. European Journal of Anesthesiology 2001, 18:36-42.
85. Watts B.V., Grady T.A. Tramadol-induced mania. American Journal of Psychiatry 1997, 154:1624.
86. Williams H.J. Tramadol hydrochloride: Something new in oral analgesic therapy. Current Therapeutic Research 1997, 58:215-226.
87. Wilson S., Bell C., Coupland N., Nutt D. Sleep changes during long-term treatment of depression with fluvoxamine-a home-based study. Psychopharmacology 2000, 149:360-365.
88. Zarate C.A., Singh J., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Manji H. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006, 63:856-864.
89. Zolezzi M., Al Mohaimeed S.A. Seizures with intravenous codeine phosphate. The Annals of Pharmacotherapy 2001, 35:1211-1213.